US clinical stage biotech Rapport Therapeutics (Nasdaq: RAPP) has announced the appointment of Dr Jeffrey Sevigny as chief ...

Rapport Therapeutics (RAPP) announced the appointment of Dr. Jeffrey Sevigny as chief medical officer, CMO, effective immediately. Dr. Sevigny ...

Results of positron emission tomography (PET) trial and second multiple ascending dose (MAD-2) trial support RAP-219's transformative potential ...

Precision Biosciences' ARCUS platform offers high precision and versatility, supporting in vivo gene editing therapies, and ...

Dr. Sevigny is a physician-scientist with more than 15 years of leadership in translational and clinical drug development, including as chief medical officer at Prevail Therapeutics, a wholly ...

Dr. Sevigny, a seasoned leader in drug development, brings over 15 years of experience to the role, having previously served as CMO at Prevail Therapeutics (NASDAQ:PRVL) and senior vice president ...

Meanwhile, Prevail Therapeutics is developing a gene therapy for a form of Parkinson's that is caused by mutations in the GBA1 gene, and Aspen Neuroscience is working on a personalised stem cell ...

Synopsis: In a case with implications for the litigious molecular diagnostics space and written description law, Chief Judge Connolly ...

NFI Group Inc. ( NFI-T) stock could see a big move today after the Winnipeg-based bus maker said it swung to a profit in the ...